| |
Latest 10 SEC filings (by transaction date) for RLMD within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jan 31/24 | Jan 31/24 | Traversa Sergio | Direct Ownership | Common Stock | P - Open market or private purchase | 27,460 | $4.00 |
Jan 31/24 | Jan 31/24 | Shenouda Maged | Direct Ownership | Common Stock | P - Open market or private purchase | 6,875 | $4.06 |
Jan 31/24 | Jan 31/24 | Ence Chuck | Direct Ownership | Common Stock | P - Open market or private purchase | 13,670 | $4.05 |
Jan 31/24 | Jan 30/24 | Traversa Sergio | Direct Ownership | Common Stock | P - Open market or private purchase | 40,999 | $3.90 |
Jan 31/24 | Jan 30/24 | Shenouda Maged | Direct Ownership | Common Stock | P - Open market or private purchase | 15,000 | $3.89 |
Jan 31/24 | Jan 30/24 | Ence Chuck | Direct Ownership | Common Stock | P - Open market or private purchase | 14,500 | $3.87 |
Jan 31/24 | Jan 29/24 | Traversa Sergio | Direct Ownership | Common Stock | P - Open market or private purchase | 31,541 | $3.71 |
Jan 31/24 | Jan 29/24 | Shenouda Maged | Direct Ownership | Common Stock | P - Open market or private purchase | 10,800 | $3.65 |
Jan 31/24 | Jan 29/24 | Ence Chuck | Direct Ownership | Common Stock | P - Open market or private purchase | 10,800 | $3.65 |
Dec 19/23 | Dec 15/23 | Traversa Sergio | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 183,881 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for RLMD within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jan 31/24 | Jan 31/24 | Traversa Sergio | Direct Ownership | Common Stock | P - Open market or private purchase | 27,460 | $4.00 |
Jan 31/24 | Jan 30/24 | Traversa Sergio | Direct Ownership | Common Stock | P - Open market or private purchase | 40,999 | $3.90 |
Jan 31/24 | Jan 29/24 | Traversa Sergio | Direct Ownership | Common Stock | P - Open market or private purchase | 31,541 | $3.71 |
Jan 31/24 | Jan 31/24 | Shenouda Maged | Direct Ownership | Common Stock | P - Open market or private purchase | 6,875 | $4.06 |
Jan 31/24 | Jan 30/24 | Shenouda Maged | Direct Ownership | Common Stock | P - Open market or private purchase | 15,000 | $3.89 |
Jan 31/24 | Jan 29/24 | Shenouda Maged | Direct Ownership | Common Stock | P - Open market or private purchase | 10,800 | $3.65 |
Jan 31/24 | Jan 31/24 | Ence Chuck | Direct Ownership | Common Stock | P - Open market or private purchase | 13,670 | $4.05 |
Jan 31/24 | Jan 30/24 | Ence Chuck | Direct Ownership | Common Stock | P - Open market or private purchase | 14,500 | $3.87 |
Jan 31/24 | Jan 29/24 | Ence Chuck | Direct Ownership | Common Stock | P - Open market or private purchase | 10,800 | $3.65 |
Dec 19/23 | Dec 15/23 | Traversa Sergio | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 183,881 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |